3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Irinotecan
5
Docetaxel
4
Cisplatin
4
Carboplatin
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
pazopanib
2
palbociclib
2
liposomal doxorubicin
2
entrectinib
2
alectinib
2
Vinorelbine
2
Trastuzumab
2
Taxes
2
Radiosurgery
2
Oncolytic Virotherapy
2
Observation
2
Ipilimumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Sarcoma
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled